{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T06:59:42Z","timestamp":1780729182135,"version":"3.54.1"},"reference-count":98,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","id.theclinics.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.idc.2016.10.013","type":"journal-article","created":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T07:48:06Z","timestamp":1486021686000},"page":"179-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Antimicrobial Therapy for Legionnaire\u2019s Disease"],"prefix":"10.1016","volume":"31","author":[{"given":"Cheston B.","family":"Cunha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burke A.","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idc.2016.10.013_bib1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1128\/AAC.30.5.743","article-title":"Inhibition of Legionella pneumophilia multiplication within human macrophages by antimicrobial agents","volume":"30","author":"Vilde","year":"1986","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.idc.2016.10.013_bib2","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1183\/09031936.93.03080886","article-title":"Azithromycin concentrations at the sites of pulmonary infection","volume":"3","author":"Baldwin","year":"1990","journal-title":"Eur Respir J"},{"key":"10.1016\/j.idc.2016.10.013_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/jac\/28.suppl_C.65","article-title":"Comparative pharmacokinetic disposition of fluoroquinolones in the lung","volume":"228","author":"Wise","year":"1991","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2016.10.013_bib4","first-page":"112","article-title":"Antimicrobial penetration into polymorphonuclear leukocytes and alveolar macrophages","volume":"6","author":"Murdoch","year":"1991","journal-title":"Semin Respir Infect"},{"key":"10.1016\/j.idc.2016.10.013_bib5","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1128\/AAC.40.11.2582","article-title":"Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses","volume":"40","author":"Olsen","year":"1996","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.idc.2016.10.013_bib6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/jac\/35.3.363","article-title":"Predicting the efficacy of antimicrobial agents in respiratory infections \u2013 is tissue concentration a valid measure?","volume":"35","author":"Bergogne-Berezin","year":"1995","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2016.10.013_bib7","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/00063198-199703000-00014","article-title":"Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy","volume":"3","author":"Honeybourne","year":"1997","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.idc.2016.10.013_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0732-8893(97)00174-0","article-title":"Comparative activity of ciprofloxacin, ofloxacin, levofloxacin, and erythromycin against Legionella species by broth microdilution and intracellular susceptibility testing in HL-60 cells","volume":"30","author":"Stout","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.idc.2016.10.013_bib9","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/jac\/47.2.147","article-title":"Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila","volume":"47","author":"Jonas","year":"2001","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2016.10.013_bib10","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ijantimicag.2004.08.019","article-title":"Comparative activity of quinolones, macrolides and ketolides against Legionella species using in\u00a0vitro broth dilution and intracellular susceptibility testing","volume":"25","author":"Stout","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idc.2016.10.013_bib11","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1093\/clind\/21.Supplement_3.S265","article-title":"Antimicrobial chemotherapy for legionnaires disease; a review","volume":"21","author":"Edelstein","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2016.10.013_bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jiac.2014.08.034","article-title":"Imipenem therapy for Legionnaires disease","volume":"21","author":"Edelstein","year":"2015","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.idc.2016.10.013_bib13","doi-asserted-by":"crossref","first-page":"759138","DOI":"10.1155\/2014\/759138","article-title":"Duration of antimicrobial therapy in community acquired pneumonia: less is more","volume":"2014","author":"Pinzone","year":"2014","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.idc.2016.10.013_bib14","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1473-3099(14)70713-3","article-title":"Epidemiology and clinical management of Legionnaires disease","volume":"14","author":"Phin","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.idc.2016.10.013_bib15","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0140-6736(15)60078-2","article-title":"Legionnaire\u2019s disease","volume":"387","author":"Cunha","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.idc.2016.10.013_bib16","first-page":"140","article-title":"Treatment of Legionnaires disease","volume":"13","author":"Klein","year":"1998","journal-title":"Semin Respir Infect"},{"key":"10.1016\/j.idc.2016.10.013_bib17","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1586\/14787210.4.6.995","article-title":"Current clinical management of Legionnaires disease","volume":"4","author":"Garcia-Vidal","year":"2006","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.idc.2016.10.013_bib18","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/QCO.0b013e328336835b","article-title":"An update on Legionella","volume":"23","author":"Carratala","year":"2010","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.idc.2016.10.013_bib19","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3109\/00365540903359895","article-title":"Disseminated Legionella pneumophila infection in an immunocompromised patient treated with tigecycline","volume":"42","author":"Valve","year":"2010","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.idc.2016.10.013_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2147\/IDR.S6030","article-title":"Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia","volume":"4","author":"Townsend","year":"2011","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.idc.2016.10.013_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/MD.0b013e31827f6104","article-title":"Community-Acquired Legionella pneumophila pneumonia. A single center experience with 214 hospitalized sporadic cases over 15 years","volume":"92","author":"Viasus","year":"2013","journal-title":"Medicine"},{"key":"10.1016\/j.idc.2016.10.013_bib22","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1378\/chest.125.5.1913","article-title":"Empiric therapy of community-acquired pneumonia: guidelines for the perplexed?","volume":"125","author":"Cunha","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.idc.2016.10.013_bib23","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s15010-015-0793-7","article-title":"High variability among Emergency Departments in 3rd-generation cephalosporins and fluoroquinolones use for community-acquired pneumonia","volume":"43","author":"Batard","year":"2015","journal-title":"Infection"},{"key":"10.1016\/j.idc.2016.10.013_bib24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1358\/dot.1998.34.2.485184","article-title":"Current concepts in the antimicrobial therapy of community-acquired pneumonia","volume":"34","author":"Cunha","year":"1998","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.idc.2016.10.013_bib25","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jama.2015.3858","article-title":"Empirical therapy of community-acquired pneumonia: advancing evidence or just more doubt?","volume":"314","author":"Mandell","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.idc.2016.10.013_bib26","doi-asserted-by":"crossref","first-page":"E71","DOI":"10.1111\/j.1469-0691.2011.03759.x","article-title":"Doxycycline vs. macrolides in combination therapy for treatment of community-acquired pneumonia","volume":"18","author":"The","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idc.2016.10.013_bib27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11908-013-0327-3","article-title":"Determining the duration of therapy for patients with community-acquired pneumonia","volume":"15","author":"Scalera","year":"2013","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.idc.2016.10.013_bib28","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s00134-002-1304-8","article-title":"Severe pneumonia due to L.\u00a0pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy","volume":"28","author":"Gacouin","year":"2002","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.idc.2016.10.013_bib29","first-page":"282","article-title":"Failure of erythromycin\/rifampicin treatment of Legionella pneumonia","volume":"10","author":"Mercatello","year":"1985","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.idc.2016.10.013_bib30","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/jac\/22.3.389","article-title":"Failure of treatment of Legionella pneumonia with ciprofloxacin","volume":"22","author":"Kurz","year":"1988","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2016.10.013_bib31","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1093\/jac\/dku196","article-title":"Isolation of ciprofloxacin-resistant Legionella pneumophila in a patient with severe pneumonia","volume":"69","author":"Bruin","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2016.10.013_bib32","first-page":"1","article-title":"Legionella spp. and Legionnaires disease","volume":"56","author":"Diederen","year":"2008","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.idc.2016.10.013_bib33","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(15)60733-4","article-title":"Community-acquired pneumonia","volume":"386","author":"Prina","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.idc.2016.10.013_bib34","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/0002-9343(84)90793-9","article-title":"Failure of erythromycin in treatment of Legionella micdadei pneumonia","volume":"76","author":"Rudin","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.idc.2016.10.013_bib35","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1086\/320526","article-title":"Persistently positive culture results in a patient with community-acquired pneumonia due to Legionella pneumophila","volume":"32","author":"Tan","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2016.10.013_bib36","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1345\/aph.1Q074","article-title":"Role of rifampin-based combination therapy for severe community-acquired Legionella pneumophila pneumonia","volume":"45","author":"Vamer","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.idc.2016.10.013_bib37","doi-asserted-by":"crossref","first-page":"161067","DOI":"10.1097\/00019048-199405001-00007","article-title":"Transitional antibiotic therapy","volume":"3","author":"Quintiliani","year":"1994","journal-title":"Infect Dis Clin Prac"},{"key":"10.1016\/j.idc.2016.10.013_bib38","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.mcna.2006.07.009","article-title":"Oral antibiotic therapy of serious systemic infections","volume":"90","author":"Cunha","year":"2006","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.idc.2016.10.013_bib39","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0002-9343(01)00934-2","article-title":"Intravenous to oral switch therapy in community-acquired pneumonia","volume":"111","author":"Cunha","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.idc.2016.10.013_bib40","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jemermed.2004.02.023","article-title":"Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies in the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy","volume":"27","author":"Katz","year":"2004","journal-title":"J\u00a0Emerg Med"},{"key":"10.1016\/j.idc.2016.10.013_bib41","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4103\/0253-7613.161258","article-title":"Antimicrobial drug prescribing patterns for community-acquired pneumonia in hospitalized patients: a retrospective pilot study from New Delhi, India","volume":"47","author":"Kotwant","year":"2015","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.idc.2016.10.013_bib42","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1183\/09031936.03.00045202","article-title":"Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia","volume":"21","author":"Torres","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.idc.2016.10.013_bib43","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/jac\/dkg035","article-title":"Pharmacokinetic aspects of levofloxacin 500\u00a0mg once daily during sequential intravenous\/oral therapy in patients with lower respiratory tract infections","volume":"51","author":"Furlanut","year":"2003","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2016.10.013_bib44","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1086\/377539","article-title":"High-dose, short course levofloxacin for community-acquired pneumonia: a new treatment paradigm","volume":"37","author":"Dunbar","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2016.10.013_bib45","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1185\/030079904X2556","article-title":"Clinical implications of 750\u00a0mg 5\u00a0day levofloxacin for the treatment of community-acquired pneumonia","volume":"20","author":"File","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.idc.2016.10.013_bib46","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1128\/AAC.47.1.444-445.2003","article-title":"Moxifloxacin for community-acquired pneumonia","volume":"47","author":"Rijinders","year":"2003","journal-title":"Antimicrobial Agents Chemother"},{"key":"10.1016\/j.idc.2016.10.013_bib47","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0954-6111(03)00166-5","article-title":"Sequential IV\/PO moxifloxacin treatment of patients with severe community-acquired pneumonia","volume":"97","author":"Lode","year":"2003","journal-title":"Respir Med"},{"key":"10.1016\/j.idc.2016.10.013_bib48","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1086\/341983","article-title":"Doxycycline for treatment of community-acquired pneumonia","volume":"35","author":"Johnson","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2016.10.013_bib49","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1086\/377615","article-title":"Doxycycline for community-acquired pneumonia","volume":"37","author":"Cunha","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2016.10.013_bib50","series-title":"Antibiotic essentials","year":"2016"},{"key":"10.1016\/j.idc.2016.10.013_bib51","series-title":"Pneumonia essentials","year":"2010"},{"key":"10.1016\/j.idc.2016.10.013_bib52","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4161\/viru.23856","article-title":"Antimicrobial stewardship programs (ASPs): the devil is in the details","volume":"4","author":"Cunha","year":"2013","journal-title":"Virulence"},{"key":"10.1016\/j.idc.2016.10.013_bib53","series-title":"Antimicrobial stewardship: principles & practice","first-page":"1","article-title":"Principles of Stewardship","author":"Cunha","year":"2016"},{"key":"10.1016\/j.idc.2016.10.013_bib54","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.idc.2012.11.008","article-title":"What is the role of antimicrobial stewardship in improving outcomes of patients with CAP?","volume":"27","author":"Nussenblatt","year":"2013","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.idc.2016.10.013_bib55","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/QCO.0b013e32835d0a8f","article-title":"Antimicrobial stewardship in the management of community-acquired pneumonia","volume":"26","author":"Hurst","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.idc.2016.10.013_bib56","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s15010-012-0362-2","article-title":"Targets for antibiotic and healthcare resource stewardship in inpatient community-acquired pneumonia: a comparison of management practices with National Guideline Recommendations","volume":"41","author":"Jenkins","year":"2013","journal-title":"Infection"},{"key":"10.1016\/j.idc.2016.10.013_bib57","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1378\/chest.110.4.965","article-title":"A\u00a0prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia: the optimum duration of therapy","volume":"110","author":"Siegel","year":"1996","journal-title":"Chest"},{"key":"10.1016\/j.idc.2016.10.013_bib58","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1086\/428054","article-title":"Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia","volume":"2","author":"Davis","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2016.10.013_bib59","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2165\/00019053-199400052-00005","article-title":"Cost-effectiveness and vale of an IV switch","volume":"5","author":"Jewesson","year":"1994","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.idc.2016.10.013_bib60","series-title":"Antimicrobial stewardship: principles & practice","first-page":"334","article-title":"Pharmacoeconomic considerations in antimicrobial stewardship programs","author":"Cunha","year":"2016"},{"key":"10.1016\/j.idc.2016.10.013_bib61","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.ajic.2015.12.026","article-title":"Evaluating the impact of an antimicrobial stewardship program on the length of stay of immune-competent adult patients admitted to a hospital ward with a diagnosis of community-acquired pneumonia: a quasi-experimental study","volume":"44","author":"DiDiodato","year":"2016","journal-title":"Am J Infect Control"},{"issue":"8","key":"10.1016\/j.idc.2016.10.013_bib62","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1093\/jac\/dkw129","article-title":"What prevents the intravenous to oral antibiotic switch? A qualitative study of hospital doctors accounts of what influences their clinical practice","volume":"71","author":"Broom","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2016.10.013_bib63","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/jac\/31.suppl_C.111","article-title":"The problems of treating atypical pneumonia","volume":"31","author":"Schlick","year":"1993","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2016.10.013_bib64","article-title":"Management of community-acquired pneumonia in an Australian regional hospital","author":"Trad","year":"2015","journal-title":"Aust J Rural Health"},{"key":"10.1016\/j.idc.2016.10.013_bib65","first-page":"13870","article-title":"Coverage of atypical pathogens for hospitalized patients with community-acquired pneumonia is not guided by clinical parameters","volume":"143","author":"Piso","year":"2013","journal-title":"Swiss Med Wkly"},{"issue":"1","key":"10.1016\/j.idc.2016.10.013_bib66","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.idc.2016.10.012","article-title":"Laboratory tests for legionnaire\u2019s disease","volume":"31","author":"Dunne","year":"2017","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.idc.2016.10.013_bib67","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.mimet.2013.04.010","article-title":"Two years\u2019 performance of an in-house ELISA for diagnosis of Legionnaire\u2019s disease: detection of specific IgM and IgG antibodies against Legionella pneumophila serogroup 1, 3, and 6 in human serum","volume":"94","author":"Elverdal","year":"2013","journal-title":"J\u00a0Microbiol Methods"},{"key":"10.1016\/j.idc.2016.10.013_bib68","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1086\/428059","article-title":"Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy","volume":"40","author":"Mykietiuk","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2016.10.013_bib69","first-page":"871","article-title":"Diagnosis of Legionella infection of Legionnaire\u2019s disease","volume":"23","author":"Den Boer","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.idc.2016.10.013_bib70","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1017\/ice.2015.113","article-title":"Diagnostic Errors that lead to inappropriate antimicrobial use","volume":"36","author":"Filice","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.idc.2016.10.013_bib71","doi-asserted-by":"crossref","first-page":"761","DOI":"10.14423\/SMJ.0000000000000386","article-title":"Characteristic predictors that increase the pretest probability of Legionnaires disease: \u201cDon\u2019t order a test just because you can\u201d revisited.\u201d","volume":"108","author":"Cunha","year":"2015","journal-title":"South Med J"},{"key":"10.1016\/j.idc.2016.10.013_bib72","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.hrtlng.2007.12.003","article-title":"Severe Legionella pneumonia: rapid diagnosis with Winthrop-University Hospital\u2019s weighted point score system (modified)","volume":"37","author":"Cunha","year":"2008","journal-title":"Heart Lung"},{"key":"10.1016\/j.idc.2016.10.013_bib73","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1046\/j.1469-0691.2000.0194f.x","article-title":"The diagnostic significance of relative bradycardia in infectious disease","volume":"6","author":"Cunha","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idc.2016.10.013_bib74","first-page":"395","article-title":"The clinical diagnosis of Legionnaires disease: the diagnostic value of combining non-specific laboratory tests","volume":"56","author":"Cunha","year":"2008","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.idc.2016.10.013_bib75","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.amjmed.2015.01.030","article-title":"Clinical diagnosis of legionnaire\u2019s disease: six characteristic criteria","volume":"128","author":"Cunha","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.idc.2016.10.013_bib76","first-page":"222","article-title":"The clinical efficacy of fluoroquinolone and macrolide combination therapy compared with single-agent therapy against community-acquired pneumonia caused by Legionella pneumophila","volume":"10","author":"Wozniak","year":"2009","journal-title":"Br Inf Soc"},{"key":"10.1016\/j.idc.2016.10.013_bib77","doi-asserted-by":"crossref","DOI":"10.1111\/crj.12379","article-title":"Overview of antimicrobial options for Mycoplasma pneumoniae pneumonia: focus on macrolide resistance","author":"Cao","year":"2015","journal-title":"Clin Respir J"},{"key":"10.1016\/j.idc.2016.10.013_bib78","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.diagmicrobio.2004.02.005","article-title":"Doxycycline use for community-acquired pneumonia: contemporary in\u00a0vitro spectrum of activity against Streptococcus pneumoniae (1999\u20132002)","volume":"49","author":"Jones","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.idc.2016.10.013_bib79","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1086\/313976","article-title":"Bacteremic pneumonia due to multi-drug resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin","volume":"31","author":"Fogarty","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2016.10.013_bib80","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1086\/318157","article-title":"Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin","volume":"31","author":"Kelley","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2016.10.013_bib81","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1086\/341978","article-title":"Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin resistant Streptococcus pneumoniae","volume":"35","author":"Lonks","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2016.10.013_bib82","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJM200202213460820","article-title":"Emergence of macrolide resistance during treatment of pneumococcal pneumonia","volume":"346","author":"Musher","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2016.10.013_bib83","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/s10096-004-1214-5","article-title":"Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens","volume":"23","author":"Hoefken","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.idc.2016.10.013_bib84","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1378\/chest.125.6.2135","article-title":"Levofloxacin efficacy in the treatment of community-acquired legionellosis","volume":"125","author":"Yu","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.idc.2016.10.013_bib85","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1469-0691.2006.01394.x","article-title":"Legionella: macrolides or quinolones?","volume":"3","author":"Pedro-Botet","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idc.2016.10.013_bib86","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1378\/chest.128.3.1401","article-title":"Fluoroquinolones vs macrolides in the treatment of Legionnaires disease","volume":"128","author":"Sabria","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.idc.2016.10.013_bib87","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1471-2334-12-159","article-title":"#08 Study Group. Switch therapy in hospitalized patients with community-acquired pneumonia: tigecycline vs. levofloxacin","volume":"12","author":"Ramirez","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.idc.2016.10.013_bib88","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1185\/030079904125003304","article-title":"Efficacy of 750\u00a0mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens","volume":"20","author":"Dunbar","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.idc.2016.10.013_bib89","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1093\/jac\/dku159","article-title":"Quinolones versus macrolides in the treatment of legionellosis: a systematic review and meta-analysis","volume":"69","author":"Burdet","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.idc.2016.10.013_bib90","first-page":"711","article-title":"Severe community-acquired pneumonia","volume":"12","author":"Cunha","year":"1997","journal-title":"J\u00a0Crit Ilness"},{"key":"10.1016\/j.idc.2016.10.013_bib91","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1093\/cid\/cis242","article-title":"Impact of an antimicrobial stewardship intervention on shortening the duration of therapy for community-acquired pneumonia","volume":"54","author":"Avdic","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2016.10.013_bib92","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1001\/jama.1978.03290110067022","article-title":"Legionnaires disease. Clinical findings and one-year follow-up","volume":"240","author":"Lattimer","year":"1978","journal-title":"JAMA"},{"key":"10.1016\/j.idc.2016.10.013_bib93","first-page":"224","article-title":"The protean manifestations of Legionnaires disease","volume":"19","author":"Woodhead","year":"1985","journal-title":"J\u00a0R Coll Physicians Lond"},{"key":"10.1016\/j.idc.2016.10.013_bib94","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/thx.41.8.635","article-title":"Legionnaires disease: a review of 79 community acquired cases in Nottingham","volume":"41","author":"Woodhead","year":"1986","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.idc.2016.10.013_bib95","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.idc.2016.10.008","article-title":"Legionnaire\u2019s disease mimics: a clinical perspective","volume":"31","author":"Cunha","year":"2017","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.idc.2016.10.013_bib96","series-title":"Antibiotic essentials","first-page":"474","article-title":"Infectious disease differential diagnosis","author":"Cunha","year":"2016"},{"key":"10.1016\/j.idc.2016.10.013_bib97","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1080\/00365540903147035","article-title":"Empiric antimicrobial therapy of community-acquired pneumonia: clinical diagnosis versus procalcitonin levels","volume":"41","author":"Cunha","year":"2009","journal-title":"Scand J Infect Dis"},{"key":"10.1016\/j.idc.2016.10.013_bib98","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11096-004-7039-6","article-title":"A\u00a0clinical and economic study of community-acquired pneumonia between single versus combination therapy","volume":"27","author":"Hasali","year":"2005","journal-title":"Pharm World Sci"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089155201630099X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089155201630099X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T01:21:30Z","timestamp":1692667290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089155201630099X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S089155201630099X"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2016.10.013","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial Therapy for Legionnaire\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2016.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}